Advancing cancer therapies. At the speed of light

Advancing cancer therapies. At the speed of light.

Hemerion® develops a unique and disruptive technology to treat glioblastoma.
A breakthrough therapy for glioblastoma patients

A breakthrough therapy for glioblastoma patients

Promising early clinical results

Promising early clinical results

A disruptive technology to tackle brain cancer and glioblastoma


Galien Prize MedStartup

Hemerion and Mount Sinai Health System nominated for the Galien MedStartup Awards 2021

September 22, 2021

Hemerion and its clinical partner Mount Sinai Health System have been nominated for the 8th edition of the Galien MedStartUp Awards, the innovation prize created by the Galien Foundation and… ...

Read more

Hemerion ships its devices to Erasmus Hospital

Hemerion technology to be further evaluated in the DOSINDYGO multi-center clinical trial

July 22, 2021

The Hemerion technology, which associates drugs and photonic treatments against glioblastoma, is to be evaluated in the DOSINDYGO clinical trial.This new clinical trial is sponsored by CHU de Lille (PI… ...

Read more

Hemerion at the Brain Tumor Symposium in Miami

The Hemerion technology presented at the Miami Global Brain Tumor Symposium

June 2, 2021

Pr. Nicolas Reyns, Head of the neurosurgery oncology dept. of the University Hospital of Lille, has been developing photodynamic therapy since 2010 in partnership with the Inserm laboratory U1189 OncoThAI.… ...

Read more